Tallac Therapeutic will present new data from ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate from our Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to promote anti-tumor immunity at the upcoming SITC annual meeting taking place Nov. 10–14, 2021 in Washington, DC

Title:
ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity (Abstract 780)

Presentation Time:
November 12 – 14, 2021, 7:00am – 5:00pm ET

Location:
Poster Hall